CustoMED key facts
as of Oct 2026- Developer of surgical planning and personalised implant software designed to enable on-site creation of patient-specific medical devices.
- CustoMED is valued at approximately $7.1M as of Oct 2026 (last reported valuation).
- It has raised $6.0M; the latest was Accelerator/Incubator in Apr 2026.
- Notable investors include Innovation Authority, ARC Innovation Center, Avishai Abrahami, Flag Capital, Longevity Venture Partners — 6 tracked in total.
- Status: Privately Held (backing).
CustoMED's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch CustoMED: the Monday email on marks, rounds and moves
CustoMED funding rounds
No funding rounds for CustoMED are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
CustoMED valuation
CustoMED's last reported valuation was $7.1 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
CustoMED investors
6 investors are on record for CustoMED, including Innovation Authority, ARC Innovation Center, Avishai Abrahami and Flag Capital.
About CustoMED
Developer of surgical planning and personalised implant software designed to enable on-site creation of patient-specific medical devices. The company's platform converts medical imaging into interactive anatomical models, supports automated segmentation, surgical planning, and generation of patient-specific instruments for local printing, enabling surgeons and healthcare providers to improve surgical precision, reduce procedure time, and deliver customized treatments efficiently.
- Sector
- Healthcare
- HQ
- Ramat Gan, Israel
- Founded
- 2023
- Employees
- 17
- Website
- customed.ai/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.